In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

Eliz­a­beth Mi­ly, the new chief of the strat­e­gy and busi­ness de­vel­op­ment group at Bris­tol My­ers Squibb, has struck her first high-pro­file col­lab­o­ra­tion since suc­ceed­ing Paul Bion­di. In putting down $65 mil­lion up­front, she’s al­so sig­nal­ing where the phar­ma gi­ant — with a new­ly-con­sol­i­dat­ed pipeline fea­tur­ing a slate of on­col­o­gy and hema­tol­ogy drugs from Cel­gene — is head­ed for the next wave of can­cer ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER